In patients with heart failure, a reduced ejection fraction, and iron deficiency, intravenous ferric carboxymaltose improves quality of life and functional capacity; clinical outcomes are unclear.
New research findings are summarized in a short video.
To see the full article, follow this link: https://nej.md/44rzIe4